Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danirixin PK and Safety in Healthy Elderly Japanese Males
NCT03136380Phase 1Completed
- Sponsor
- GSK
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danirixin in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event (AE) and Serious Adverse Events up to 21 days, Change From Baseline in Clinical Laboratory Parameters up to 48 hours and 8 more. Started May 2017; status: completed.
02
Drugs
danirixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03136380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136380.